近岸蛋白(688137.SH)：股東違反承諾減持致歉並承諾購回
格隆匯7月8日丨近岸蛋白(688137.SH)公佈，近日收到公司股東杭州暢遂股權投資合夥企業（有限合夥）（簡稱“杭州暢遂”）和淄博璟麗創業投資合夥企業（有限合夥）（簡稱“淄博璟麗”）送達的《關於減持蘇州近岸蛋白質科技股份有限公司股票的情況説明》。
杭州暢遂、淄博璟麗持有的近岸蛋白股票於2024年6月26日解禁，杭州暢遂、淄博璟麗的股東於6月20日指示工作人員準備進行減持，同時，杭州暢遂、淄博璟麗於6月21日通知近岸蛋白擬減持所持股票。由於上述股東工作人員未充分關注到杭州暢遂、淄博璟麗在公司《首次公開發行股票並在科創板上市招股説明書》等文件中所作出的承諾，以及杭州暢遂、淄博璟麗內部信息溝通不及時，杭州暢遂於2024年6月26日至2024年7月1日期間通過集中競價合計減持近岸蛋白股份148,549股，減持金額約480萬元，未提前三個交易日披露減持計劃；淄博璟麗於2024年6月26日至2024年6月28日期間通過集中競價合計減持近岸蛋白股份160,150股，減持金額約517萬元，未提前三個交易日披露減持計劃。
杭州暢遂、淄博璟麗的本次減持系因內部信息溝通不及時，工作人員未深刻理解減持規則及承諾，並非主觀故意。杭州暢遂、淄博璟麗收到公司的反饋後，立即停止了減持行為，並於第一時間組織自查和梳理減持情況，起草了情況説明，與公司進行了充分溝通。杭州暢遂和淄博璟麗對此次違反承諾的減持行為深表歉意，杭州暢遂和淄博璟麗及相關責任人員已進行了深刻反省，並承諾加強風控管理以及對證券法規的學習。今後，將繼續嚴格遵守國家法律、法規及證券監管部門、證券交易所的監管要求進行減持並認真履行信息披露義務。杭州暢遂和淄博璟麗承諾在規則允許的範圍內，儘快購回違規減持近岸蛋白的股份，並承諾將購回股份產生的收益（如有）全部繳納至近岸蛋白指定賬户。近岸蛋白將加強與股東之間的溝通，督促杭州暢遂和淄博璟麗進一步加強相關人員對法律、法規和規範性文件的學習，嚴格管理公司股票賬户，審慎操作，杜絕該類情況再次發生。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
